Inhibition of the CDK4/6-Cyclin D-Rb Pathway by Ribociclib Augments Chemotherapy and Immunotherapy in Renal Cell Carcinoma

Figure 1

The sensitivity of RCC cancer cell lines and normal cells to ribociclib. (a) The differential antiproliferative effects of ribociclib in multiple RCC cell lines and normal cells. BJ is fibroblast cells. HEK-293, RPTEC/TERT1, and CCD1103 are normal kidney cell lines. 786-O, SW839, CaKi-2, CaKi-1, and A-498 are clear cell RCC cell lines. 769-P, A-704, UM-RC-2, and ACHN are renal adenocarcinoma cell lines. Results shown are relative to control (value set as 1). (b) IC₅₀ values of ribociclib in RCC and normal cells. Cell lines are ordered from left to right with low to high IC₅₀. # indicates that the IC₅₀ value is more than the highest dose tested. (c) The differential proapoptotic effects (shown by % of Annexin V) of ribociclib in multiple RCC cell lines and normal cells. Cells were treated with the indicated doses for 72 h prior to proliferation and apoptosis analysis. , compared to control (value is 1).

(a)

(b)

(c)